NAMS NAMS
Company Profile ↓Company Overview
NAMS (NAMS) is a publicly traded company listed on with a market capitalization of $3.14B. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.03.
Recent Developments
- Dec 2025 Revenue of $22.50M (-50.6% YoY); net profit $-203.82M.
- Trailing 12 Months Year-on-year growth — revenue -50.6%.
- 5-Year Trend Long-term compounding — revenue CAGR -39.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -39.71% |
| 1 Year: | -50.61% |
Stock Price Performance
| 1 Year: | +26.59% |
| 6 Months: | -16.88% |
| 3 Months: | -8.14% |
| 1 Month: | -25.87% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)35.26 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -39.7% CAGR over 5 years.
- Trading 33.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8.63M | 1.72M | 2.94M | 1.40M | 2.28M | 29.11M | 2.98M | 19.14M | 348.00K | 32.00K | 3.04M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | 71.90M | 54.78M | 55.49M | 66.01M | 61.46M |
| Operating Income | -39.85M | -42.48M | -49.56M | -55.48M | -52.58M | -25.00M | -68.92M | -35.63M | -55.14M | -65.98M | -58.42M |
| EBITDA | - | - | - | - | - | - | -68.87M | -35.59M | -55.08M | -65.92M | -58.36M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | -39.53M | -17.36M | -72.00M | -74.92M | -48.44M |
| Tax Provision | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Net Income | -42.02M | -38.29M | -47.13M | -93.77M | -39.01M | -16.65M | -39.53M | -17.36M | -72.00M | -74.92M | -48.44M |
| Diluted EPS | -0.51 | -0.47 | -0.57 | -1.06 | -0.41 | -0.18 | -0.34 | -0.15 | -0.61 | - | -0.40 |
| R&D Expense | 40.42M | 34.34M | 43.37M | 42.43M | 38.38M | 35.70M | 44.75M | 27.52M | 30.97M | - | 38.01M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 102.69M | 14.09M | 45.56M | 22.50M |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 106.25M | 197.06M | 221.85M | 248.19M |
| Operating Income | - | -3.56M | -182.97M | -176.29M | -225.68M |
| EBITDA | - | -22.34M | -182.92M | -176.18M | -225.46M |
| Interest Expense | 411.00K | 287.00K | 0 | 0 | - |
| Pretax Income | - | -22.63M | -176.91M | -241.60M | -203.82M |
| Tax Provision | - | 0 | 27.00K | -1.00K | 0 |
| Net Income | - | -22.63M | -176.94M | -241.60M | -203.82M |
| Diluted EPS | - | -1.19 | -2.15 | -2.56 | -1.78 |
| R&D Expense | 28.97M | 86.74M | 159.42M | 151.41M | 141.83M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Total Assets | - | - | 478.50M | 347.10M | 864.62M | 769.28M |
| Current Assets | - | - | 477.98M | 346.79M | 863.41M | 675.70M |
| Cash & Equivalents | - | - | 467.73M | 340.45M | 771.74M | 490.00M |
| Inventory | - | - | - | - | - | - |
| Receivables | - | - | 2.07M | 1.88M | 21.30M | 23.15M |
| Total Liabilities | - | - | 48.43M | 58.70M | 107.12M | 85.85M |
| Current Liabilities | - | - | 36.06M | 49.90M | 106.92M | 85.79M |
| Long Term Debt | - | - | - | - | - | - |
| Total Debt | - | - | 126.00K | 60.00K | 448.00K | 202.00K |
| Total Equity | -73.03M | - | 430.07M | 288.39M | 757.50M | 683.43M |
| Shares Outstanding | - | - | 81.56M | 82.47M | 108.06M | 114.40M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 10.66M | -141.22M | -158.56M | -147.78M |
| Investing Cash Flow | - | -221.00K | -24.00K | -62.85M | -174.92M |
| Financing Cash Flow | - | 391.90M | 8.91M | 659.51M | 29.52M |
| Capital Expenditure | - | -221.00K | -24.00K | -672.00K | -246.00K |
| Free Cash Flow | - | 10.44M | -141.24M | -159.24M | -148.03M |
| Net Change in Cash | - | 402.35M | -132.33M | 438.10M | -293.18M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | -3.5% | -1,298.6% | -386.9% | -1,002.9% |
| Net Margin % | - | -22.0% | -1,255.8% | -530.3% | -905.7% |
| ROE % | - | -5.3% | -61.4% | -31.9% | -29.8% |
| ROCE % | - | -0.8% | -61.6% | -23.3% | -33.0% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NAMS
NewAmsterdam Pharma Maps Obicetrapib Strategy as PREVAIL Interim Nears
NewAmsterdam Pharma (NASDAQ:NAMS) used its annual Investor Day to outline its cardiovascular outcomes strategy for obicetrapib, provide updates on additional clinical programs and discuss commercial preparations ahead of a potential Europea…
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Lags Revenue Estimates
NewAmsterdam Pharma Company N.V. (NAMS) delivered earnings and revenue surprises of -8.33% and -45.41%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?…
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
– Announced positive CHMP opinion recommending marketing authorization for obicetrapib and obicetrapib/ezetimibe – – PREVAIL interim analysis planned for 4Q2026 with result expected in 1Q2027 – – Topline data from RUBENS Phase 3 expected by…
NewAmsterdam Pharma to Host Investor Day on August 5, 2026
NAARDEN, The Netherlands and MIAMI, July 29, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines…
NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
- Positive CHMP opinion supports potential commercialization of obicetrapib monotherapy and obicetrapib/ezetimibe fixed-dose combination in Europe - - Recommendation based on positive Phase 3 BROADWAY, BROOKLYN, and TANDEM data - - European…
Attovia Therapeutics Appoints John W. Smither to Board of Directors
Mr. Smither brings extensive public company board and audit committee experience in the biotechnology sectorSAN CARLOS, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (“Attovia” or the “Company”), a clinical-stage biop…
NAMS — Frequently Asked Questions
What is the current share price of NAMS?
As of 2026-08-05 17:25 PDT, NAMS trades at $27.42 on NASDAQ/NYSE. Its 52-week range is $21.66 to $41.45.
What is the market capitalisation of NAMS?
NAMS has a market capitalisation of $3.14B on NASDAQ/NYSE.
What is the P/E ratio of NAMS?
NAMS trades at a trailing price-to-earnings (P/E) ratio of -15.39. Its price-to-book (P/B) ratio is 4.59.
What is the return on equity (ROE) of NAMS?
NAMS has a return on equity (ROE) of -29.82%. Its return on capital employed (ROCE) is -33.02%.
Is NAMS a good stock to buy?
This page provides a data-driven analysis of NAMS, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.